LBP Expertise List Labs is a long-standing CDMO with over 45 years of experience in live biotherapeutic products and bacterial-based therapeutics, offering process development, scale up, analytical development, QC testing, aseptic filling, purification, lyophilization, and encapsulation capacity to support clinical trials and future commercial launch.

Full Service CDMO Their end-to-end capabilities across fermentation of bacteria, toxin and endotoxin production, and cGMP manufacturing position them as a one-stop partner for developers seeking both LBPs and bacterial-derived therapeutics, enabling faster timelines and tighter coordination.

Specialized Biologics With a portfolio including native and recombinant toxins, LPS/endotoxins, and bacterial proteins, List Labs can support research, assay development, and manufacturing needs for toxin-related studies, diagnostics, and therapeutic development.

Strategic Partnerships Past collaborations with Genome & Company and BetterLife Pharma, along with a history of publicized partnerships and leadership changes, indicate a network-ready posture for co-development opportunities and potential access to global program channels.

Growth Signals Revenue range of 25 to 50 million and a notable focus on LBP development suggest increasing demand for niche microbial therapeutics, presenting opportunities in early-phase manufacturing, scale-up support, and regulatory-ready process development for clinical programs.